OnKure Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
33.0%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$250Knext fiscal year
FY EPS (est.)
-$1.83next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results | 5 Nov 2026 |
| PIKture-01 Mature Data Presentation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly192.1MTarget: Sufficient to fund operations into 2029
Quarterly Net Loss Quarterly-15.2MTarget: Controlled burn rate aligned with preclinical development
OKI-355 IND-Enabling Studies Progress AnnuallyTarget: IND filing in 1H 2027
OKI-345 IND-Enabling Studies Progress AnnuallyTarget: IND filing in 1H 2027
Watch Items
- PIKture-01 Trial Mature Data ReleaseTrigger: Release of mature safety, tolerability, and clinical activity data from Parts A, B, C, and EAction: Evaluate translational insights to validate the mutant-selective PI3Kα platform chemistry
- IND Filings for OKI-355 and OKI-345Trigger: FDA acceptance of IND applications in 1H 2027Action: Initiate Phase 1 clinical trials in vascular anomalies and breast cancer respectively
- Preclinical Pipeline ExpansionTrigger: Nomination of additional mutation-selective oncology or rare disease candidatesAction: Allocate capital from the $150M private placement to expand discovery programs
Research as of 19 Jun 2026